PMID: 2091939Dec 1, 1990Paper

Establishment of stable mouse/human-human hybrid cell lines producing large amounts of anti-tetanus human monoclonal antibodies with high neutralizing activity

European Journal of Epidemiology
M KameiM Matsuda

Abstract

To establish stable hybrid cell lines producing human anti-tetanus antibody with high toxin-neutralizing activity, peripheral lymphocytes from humans hyperimmunized with tetanus toxoid were, after in vitro antigen stimulation, fused with a mouse/human heteromyeloma or human lymphoblastoid cell line and cloned. Unlike the IgM secretors (six clones), the IgG secretors we obtained (six clones) produced anti-tetanus human monoclonal antibodies with high neutralizing activity (the highest one, cell line G2, 4.3 IU/100 micrograms IgG). Appropriate combinations of three or four kinds of monoclonal antibodies of the IgG type resulted in markedly increased neutralizing activity comparable with that of anti-tetanus human polyclonal immunoglobulin preparations currently used clinically on the basis of toxin-specific IgG content. Five of these cell lines produced 10-20 micrograms of antibody per ml for more than 3 months. The cell line G2 produced 6 mg of antibody per day in serum-free medium in a 500-ml bioreactor in perfusion culture and 13-104 mg in a nude mouse. These cell lines satisfied, for the first time, the minimal requirements for applying human monoclonal antibodies to clinical use.

References

Jul 11, 1977·Biochemical and Biophysical Research Communications·M Matsuda, M Yoneda
Jan 1, 1976·Journal of Immunological Methods·A SaxonR A Robins
May 31, 1985·Biochemical and Biophysical Research Communications·Y IchimoriK Tsukamoto
Aug 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y Z PattJ L Murray
Feb 1, 1986·Cell Biology International Reports·H OhashiH Omura
Oct 1, 1985·In Vitro Cellular & Developmental Biology : Journal of the Tissue Culture Association·H MurakamiH Omura
Jul 1, 1980·Analytical Biochemistry·B R OakleyN R Morris
Feb 1, 1981·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·I EbisawaT Otsuka
Mar 4, 1982·The New England Journal of Medicine·R A MillerR Levy
Dec 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·N N TengH S Kaplan
May 1, 1984·European Journal of Immunology·R F TieboutW P Zeijlemaker
Oct 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·J W LarrickJ C Wang
Dec 1, 1982·The Journal of Clinical Investigation·F Gigliotti, R A Insel
Mar 1, 1983·Immunology Today·D Kozbor, J C Roder

❮ Previous
Next ❯

Citations

Mar 28, 1996·Journal of Immunological Methods·J A OwenZ L Jonak
Apr 29, 2005·Comparative Immunology, Microbiology and Infectious Diseases·El-Rashdy M RedwanZeinab Z El-Dardiri
Mar 8, 2003·Biologicals : Journal of the International Association of Biological Standardization·Jaeho ChinMyung Ja Choi
May 21, 2015·Journal of Immunotoxicology·Mehdi YousefiFazel Shokri
Feb 2, 2013·Journal of Immunotoxicology·Mehdi YousefiFazel Shokri
Oct 16, 2013·Human Vaccines & Immunotherapeutics·Mehdi YousefiFazel Shokri
Mar 15, 2006·Journal of Immunotherapy·Kazuko KawamuraTakashi Uchiyama
Nov 14, 2019·Neurotoxicity Research·Somayeh GhotlooFazel Shokri
Jun 11, 2021·Scientific Reports·Takeharu MinamitaniTeruhito Yasui
Aug 20, 2021·Toxicon : Official Journal of the International Society on Toxinology·Somayeh GhotlooFazel Shokri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.